## ICMJE DISCLOSURE FORM

Date: 3 April. 2024

Your Name: Kyoichi Kaira

Manuscript Title: Overcoming acquired resistance following osimertinib administration in EGFR-mutant lung

adenocarcinoma

Manuscript number (if known): TLCR-24-193

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	<b>X</b> None	
	manuscript (e.g., funding, provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	<b>X</b> None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<b>X</b> None	
4	Consulting fees	<b>X</b> None	

5	lectures, presentations,	XN	one	
	speakers bureaus,			
	manuscript writing or educational events			
6	Payment for expert	XN	one	
	testimony			
7	Support for attending meetings and/or travel	X_N	one	
8	Patents planned, issued or	XN	one	
	pending			
9	Participation on a Data Safety Monitoring Board or	X_N	one	
	Advisory Board			
10	Leadership or fiduciary role	X_N	one	
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	XN	one	
12	Receipt of equipment,	ΧN	one	
	materials, drugs, medical		one	
	writing, gifts or other			
	services			
13	Other financial or non-	XN	one	
	financial interests			
	Please summarize the above conflict of interest in the following box:  I have no conflict of interest about this study.			

Please place an "X" next to the following statement to indicate your agreement:

\_\_ X \_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## ICMJE DISCLOSURE FORM

Date: 3 April. 2024 Your Name: Hisao Imai

Manuscript Title: Overcoming acquired resistance following osimertinib administration in EGFR-mutant lung

adenocarcinoma

Manuscript number (if known): TLCR-24-193

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	XNone	
	provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	<b>X</b> None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<b>X</b> None	
4	Consulting fees	<b>X</b> None	

5	lectures, presentations,	XN	one	
	speakers bureaus,			
	manuscript writing or educational events			
6	Payment for expert	XN	one	
	testimony			
7	Support for attending meetings and/or travel	X_N	one	
8	Patents planned, issued or	XN	one	
	pending			
9	Participation on a Data Safety Monitoring Board or	X_N	one	
	Advisory Board			
10	Leadership or fiduciary role	X_N	one	
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	XN	one	
12	Receipt of equipment,	ΧN	one	
	materials, drugs, medical		one	
	writing, gifts or other			
	services			
13	Other financial or non-	XN	one	
	financial interests			
	Please summarize the above conflict of interest in the following box:  I have no conflict of interest about this study.			

Please place an "X" next to the following statement to indicate your agreement:

\_\_ X \_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## ICMJE DISCLOSURE FORM

Date: 3 April. 2024

Your Name: Hiroshi Kagamu

Manuscript Title: Overcoming acquired resistance following osimertinib administration in EGFR-mutant lung

adenocarcinoma

Manuscript number (if known): TLCR-24-193

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	XNone	
	provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	<b>X</b> None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<b>X</b> None	
4	Consulting fees	<b>X</b> None	

5	lectures, presentations,	XN	one	
	speakers bureaus,			
	manuscript writing or educational events			
6	Payment for expert	XN	one	
	testimony			
7	Support for attending meetings and/or travel	X_N	one	
8	Patents planned, issued or	XN	one	
	pending			
9	Participation on a Data Safety Monitoring Board or	X_N	one	
	Advisory Board			
10	Leadership or fiduciary role	X_N	one	
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	XN	one	
12	Receipt of equipment,	ΧN	one	
	materials, drugs, medical		one	
	writing, gifts or other			
	services			
13	Other financial or non-	XN	one	
	financial interests			
	Please summarize the above conflict of interest in the following box:  I have no conflict of interest about this study.			

Please place an "X" next to the following statement to indicate your agreement:

\_\_ X \_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.